Contact Us
Quotes News NAV
Market Watch
01 Oct EOD
SENSEX
NIFTY
GOLD
SILVER
CRUDE OIL
 
Market Info EXPAND TICKER
You are here : Corporate Information   |  Company News Details
Your Result on : Corporate Information | Company News Details
Glenmark Pharmaceuticals Ltd Back
Glenmark Pharmaceuticals consolidated net profit rises 930.34% in the June 2026 quarter
Aug 01,2026   Hrs IST

Net profit of Glenmark Pharmaceuticals rose 930.34% to Rs 482.92 crore in the quarter ended June 2026 as against Rs 46.87 crore during the previous quarter ended June 2025. Sales rose 28.52% to Rs 3931.73 crore in the quarter ended June 2026 as against Rs 3059.33 crore during the previous quarter ended June 2025.

ParticularsQuarter Ended
Jun. 2026Jun. 2025% Var.
Sales3931.733059.33 29
OPM %20.4718.98 -
PBDT816.56548.73 49
PBT643.39418.81 54
NP482.9246.87 930

Detailed Quotes
MF Holdings
Company News
Profit and Loss
Quarterly Results
Share Holding Pattern
Deliverable Volumes
Historical Prices
Board of Directors
Director's Report
Peer Comparison
Score Board
Name Change
Financial Ratios
Company Background
Company Snapshot
Balance Sheet
Site Map | Disclaimer | Circular Reports | Research Reports | About Us | Feedback | Careers | Contact Us
Useful Links
Stock : Stock Price Quotes | Stock Market India | Stock Market Global | Corporate Announcement
Market News : Corporate News | Market Commentary | Corporate Results | Economy News | Other Markets | Hot Pursuit | Futures Market
Share Market Updates : BSE Top Gainers - Sensex | NSE Top Gainers - Nifty | BSE Top Losers - Sensex | NSE Top Losers - Nifty | BSE Most Active Scrip by Volume - Sensex |
NSE Most Active Scrip by Volume - Nifty | BSE Most Active Scrip by Value - Sensex | NSE Most Active Scrip by Value - Nifty | Advances and Declinces
Derivatives : Get Quotes | Daily Settlement Prices | Put-Call Ratio | Cost Of Carry
Global Indicator : Stock Market Global | Currency | ADR Prices | FII Investments | Mutual Fund Investments
Services : Equity | Derivatives | Commodities | Mutual Fund | Portfolio Management Services (PMS) | Initial Public Offer (IPO)
Members:
Sebi Regn.No. - BSE : INB010983738 | NSE : INB230983737 | F&O : INF230983737 | NSE Currency: INE230983737 | FMC REGN.MCX : MCX/TCM/CORP/0276 | NCDEX : NCDEX/TCM/CORP/0411
Email ID for redressal of Investor Complaints : investorgrievances@manumangal.com
2012 © MANUBHAI MANGALDAS SECURITIES PVT. LTD All rights reserved Designed, developed & powered by C-MOTS Infotech (ISO 9001:2008 certified)